The efficiency and safety of low‐dosage isotretinoin therapy for Chinese acne vulgaris patients

Abstract

AbstractBackgroundAcne vulgaris is one of the most common skin conditions in dermatology clinics. Accumulating evidence has implicated oral low‐dosage isotretinoin was an effective treatment for acne with fewer side effects. Currently, the data on low‐dosage isotretinoin use in Chinese is limited.AimsTo investigate the efficiency and safety of low‐dosage isotretinoin therapy for Chinese acne patients.MethodsThree hundred and eighty‐eight patients treated with low‐dosage isotretinoin (0.2–0.4 mg/kg/d) and who completed the course (120 mg/kg) were enrolled. Medical information on the severity, duration, adverse effects, and outcome of acne was reviewed.ResultsThe majority (90.2%, n = 350) of patients achieved complete remission, and on average, patients received 13.5 months of treatment. The time between isotretinoin start and the clear date between the mild and moderate groups was not significantly different (74 ± 24 vs. 84 ± 24 days). However, it took longer to resolve for the severe acne group (112 ± 25 days). Follow‐up 1 year after completion of the isotretinoin course, 37/350 (10.6%) patients relapsed, but there was no difference in the severity of acne. There were 133 (34.3%), 40 (10.3%), and 14 (2.6%) patients who developed hypercholesterolemia, hypertriglyceridemia, and high LDL, respectively. Thirty‐two (8.2%) and 28 patients (7.2%) had elevated serum levels of alanine and aspartate aminotransferases. No values above grade 2 were detected.ConclusionsThis study reaffirms the efficacy and safety of low‐dosage oral isotretinoin in Chinese patients with acne vulgaris. Lab investigation could be performed after 2 months of therapy in healthy patients with normal baseline liver function and lipid panel tests.